What Apposite Capital does

Apposite Capital is a specialist pan-European private equity investor focused exclusively on healthcare and life sciences, founded in 2006 and headquartered at 89 Charterhouse Street, London. The firm provides institutional capital to healthcare SMEs in the UK and continental Europe through growth capital, management buyouts and buy-ins, retirement sales, and founder transitions, positioning itself as the first institutional capital provider for ambitious healthcare businesses seeking to scale. Its core service is fund management: deploying capital across multiple funds (including the recently launched Apposite Healthcare Growth I with a £100 million cornerstone commitment from the British Business Bank) and earning revenue through management fees and carried interest. The firm is regulated by the UK Financial Conduct Authority and structured as Apposite Capital LLP.

The firm's portfolio spans 30-plus investments across diverse healthcare subsectors — clinical research organizations (1Med), medical device technology (CrestOptics, Emblation, Ulthera), diagnostic laboratories (i2a, NIMGenetics), healthcare providers (Habitus, HCML, Swanton Care, Riverdale Healthcare, By the Bridge), medical products (Summit Medical, Imaging Holdings, Mirada Medical), pharmaceutical services (Kelso Pharma), digital health (CancerPartnersUK), and specialized education (Octavia House Schools). Portfolio activity has been particularly active across Italy, Switzerland, and the UK, with operating geographies also extending to Denmark and Spain. The team of 15 professionals is augmented by a network of 500-plus operating partners who provide sector expertise, deal sourcing, and value creation support.

Apposite differentiates through deep thematic sector knowledge rather than proprietary technology. Its competitive advantages are operational and relational: decades of healthcare investing experience, an extensive UK/European healthcare leader network, regulatory fluency (including European MDR and FDA pathways), and an embedded health impact framework tied to three core themes — quality, access, and innovation. Companies backed by Apposite have reportedly grown revenues and employment by over 20% per annum on average, and the firm claims 100% of portfolio companies deliver measurable health impact. Customer-facing channels are limited to direct outreach, a website, LinkedIn presence, and newsletter — consistent with a B2B fund manager rather than a product or technology business.

Name

Apposite Capital

Legal name

Apposite Capital LLP

Website

https://appositecapital.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Apposite Capital is a London-based specialist pan-European private equity firm investing exclusively in healthcare and life sciences SMEs through growth capital, management buyouts/buy-ins, retirement sales, and founder transitions, with 30+ portfolio companies and a 500-strong operating partner network.

Ownership category

akta.pro rank

Product category

Private Equity / Healthcare Investment

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Technology & Software Growth Equity (FSANACAA)

Keywords

• Healthcare private equity
• Life sciences investing
• Growth capital
• Management buyouts
• Healthcare SME investments

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management: Apposite Capital generates returns through management fees and carried interest from their healthcare-focused private equity funds. They manage funds including Fund III and the newly launched Apposite Healthcare Growth I, targeting UK health technology companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Apposite Capital is a specialist pan-European private equity firm that provides institutional capital to healthcare and life sciences SMEs through growth capital, management buyouts and buy-ins, retirement sales, and founder transitions. The firm invests across healthcare subsectors including medical devices, diagnostics, digital health, CRO/pharmaceutical services, and care providers, supporting portfolio companies with sector expertise and operating partner resources to drive growth.

Product overview

Apposite Capital is a specialist pan-European private equity firm focused exclusively on healthcare and life sciences investments. Rather than offering a unified software product, the firm provides investment capital and value creation services to healthcare SMEs through multiple mechanisms: growth capital, management buyouts and buy-ins, retirement sales, and founder transitions. The firm's portfolio spans diverse healthcare subsectors including clinical research organizations (1MED), medical device technology (CrestOptics, Emblation, Ulthera), diagnostic laboratories (i2a, NIMGenetics), healthcare providers (Habitus, HCML, Swanton Care, Riverdale Healthcare, By the Bridge), medical products (Summit Medical, Imaging Holdings, Mirada Medical), pharmaceutical services (Kelso Pharma), digital health platforms (CancerPartnersUK), and specialized education (Octavia House Schools).

Differentiator

Problem solved

Functional benefit

Products and services

• Growth Capital Investment

Quantifiable outcome

• Over 20% per annum average revenue and employment growth across portfolio companies
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• IK Partners: European mid-market private equity firm with a dedicated healthcare practice across the UK, France, Benelux, and DACH regions. Directly comparable to Apposite in mid-market European healthcare investing, though broader across other sectors.
• GHO Capital Partners: London-based specialist healthcare and life sciences private equity firm investing in European mid-market healthcare companies. Directly comparable to Apposite given shared sector focus, similar European footprint, and mid-market healthcare SME investment thesis.
• ARCHIMED: France-headquartered healthcare-dedicated private equity firm investing across medical devices, diagnostics, pharmaceuticals, and healthcare services in Europe and North America. Closely comparable as a sole-sector healthcare PE firm competing for similar European SME assets.

Broad incumbents

• Nordic Capital: Large Nordic private equity firm with a substantial dedicated healthcare practice investing across Northern Europe. Broad incumbent in the European healthcare PE landscape, with overlap on healthcare SME buyouts but operating at significantly larger fund sizes than Apposite.
• EQT Life Sciences: Amsterdam-based life sciences venture and growth investor, part of EQT. Comparable as a European healthcare/life sciences specialist, though focused more on growth equity and venture than Apposite's buyout-led SME model.
• Bridgepoint Group: London-listed European mid-market PE firm with a meaningful healthcare practice across services, products, and pharmaceuticals. Comparable as a competitor for European healthcare SME investments, though operating across multiple sectors and at larger fund sizes.
• Waterland Private Equity: Benelux-headquartered European private equity firm with a dedicated healthcare and care services practice. Comparable as a competitor in European healthcare/care provider investing, particularly in Northern Europe, though active across other verticals too.
• Cinven: Pan-European large-cap private equity firm with an active healthcare team investing in European healthcare services, products, and pharma. Comparable at the larger end of the healthcare PE market, competing for the same pool of European healthcare SMEs and growth-stage assets.
• Permira: Global private equity firm with a healthcare practice that invests across European healthcare services and life sciences. Comparable as a larger, broader-platform competitor in the European healthcare PE landscape.

Emerging players

• EVOLUTION Life Science Partners: Emerging European life sciences-focused private equity manager. Comparable as a fellow specialist life sciences PE player, though typically earlier-stage and smaller in fund size than Apposite.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/apposite-capital

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A11 records

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apposite Capital